[Comparative study of the combined effect of HCFU and dipyridamole (DP) in colorectal carcinoma--TS inhibition rate. Kinki Cooperative Study Group of Chemotherapy for Colorectal Carcinoma].
In the forty-seven medical centers in the Kinki district, a comparative trial was conducted to investigate the enhancement of the efficacy of HCEU due to dipyridamol (DP), which is a biochemical modulator in patients with colorectal cancer who have had a curative resection. The trial consisted of two comparative groups: one group (Group A) received HCFU only for five days before operation and for two years from the second week, and the other group (Group B) was given HCFU + DP for the same trial period as Group A. The total number of patients collected was 653 (Group A: 327 patients; Group B: 326 patients) during the two-year trial period from October, 1991. Thymidylate Synthetase (TS) activity in the primary lesions, which is an index of proximity effect, was measured, and the TS inhibition rate (TSIR) was calculated from the activities. The results showed that the TSIR in the primary lesions for the HCFU + DP group (Group B: 0.33) was significantly higher than that of the HCFU group (Group A: 0.27) (p = 0.0006). There was no increase in the side effects of HCFU due to combined administration with DP. From the above results, the therapy with HCFU + DP is expected to be useful for patients with colorectal cancer who have undergone curative resection.
Kanno
H
H
Dept. of Surgery, Takarazuka City Hospital, Japan.
Yoden
Y
Y
Ohashi
S
S
Utsunomiya
J
J
Oshima
A
A
Kameyama
M
M
Iwanaga
T
T
Kikkawa
N
N
Hioki
K
K
Fukuda
I
I
Mori
T
T
Yasutomi
M
M
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D004176:Dipyridamole / Q000008:administration & dosage; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage; D007564:Japan; D008297:Male; D008875:Middle Aged; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors*
D007155:Immunologic Factors; D004176:Dipyridamole; D013940:Thymidylate Synthase; C017367:carmofur; D005472:Fluorouracil